Quick Answer
Relay Therapeutics, Inc. reported R&D Expense of $99.86 million for fiscal year 2020.
Relay Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2020 | $99.86M | +42.0% |
| 2019 | $70.31M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| March 31, 2021 | $30.62M | +41.1% | +25.6% |
| September 30, 2020 | $24.38M | +33.5% | +12.5% |
| June 30, 2020 | $21.67M | +32.1% | -0.2% |
| March 31, 2020 | $21.70M | — | +18.9% |
| September 30, 2019 | $18.26M | — | +11.3% |
| June 30, 2019 | $16.40M | — | — |
- Relay Therapeutics, Inc. showed an increase of +42.0% in R&D Expense compared to the prior fiscal year.
- Over the 2019–2020 period, Relay Therapeutics, Inc.’s r&d expense has grown by 42.0% (from $70.31 million to $99.86 million).
- The most recent figure is from Relay Therapeutics, Inc.’s fiscal year 2020 report (Form 10-K), filed with the SEC on March 25, 2021.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: